The adjuvant use of N-palmitoylethanolamine and transpolydatin in the treatment of endometriotic pain

Evaluation of endometriosis-associated pain and influence of conventional treatment: a systematic review

“…6,10,12,13,15,[17][18][19][20][22][23][24][26][27][28]31,32 The main results of these studies are summarized in Table 3.…”

“…Of the 17 studies that evaluated the influence of medication on decreasing pain levels, seven evaluated one drug alone 6,13,20,[26][27][28]32 and 10 evaluated drugs in combination. 10,12,15,[17][18][19][22][23][24]31 Thus, 3 studies employed contraceptives; 24,26,27 10 used isolated progestins; 10,12,13,15,17,19,20,22,23,28 5 used GnRHa, 6,10,22,24,32 one used danazol 23 and 4 used aromatase inhibitors. 12,15,19,22 The use of aromatase inhibitors for the treatment of endometriosis and its associated symptoms is justified by the fact that endometriotic tissue over-expresses aromatase, an enzyme key for the production of estrogen, noting that endometriosis is an estrogen-dependent gynecological condition.…”

“…Two studies have evaluated the combination of N-palmitoyl ethanolamine and transpolydatin/polydatin, drugs that act on inflammation, in the treatment of pain associated with endometriosis. 18,31 Polydatin is a resveratrol glycoside that has antioxidant activities. Therefore, the combination of these drugs work on the inflammatory processes and oxidative stress involved in the development of endometriosis.…”

Inflammation and Chronic Pelvic Pain: A Biological Trigger for Depression in Women?

“…In Italy and other European states, products based on PEA are approved as therapeutics classified as "dietary foods for special medical purposes". The combination of micronized PEA and polydatin, in particular, provides significant and long-lasting relief of pelvic pain symptomatology (Table 3) [100][101][102][103][104][105]. Given the optimal safety profile of PEA, products based on this fatty acid amide may find utility as tools to control pain in pelvic disorders associated to CPP, as well as co-morbid anxiety and depression.…”

Palmitoylethanolamide: From endogenous cannabimimetic substance to innovative medicine for the treatment of cannabis dependence

“…Like cannabis, several evidences suggest that, PEA, an endogenous fatty acid, can produce anti-inflammation and anti-nociceptive activity in humans [52][53][54]. This anandamide congener appears to be able to activate cannabinoids receptors through two principal ways: directly, via CB1 and/or CB2 agonism or indirectly via AEA mediated cannabimimetic activity [55].…”